Novel insights into the immunotherapy of soft tissue sarcomas: Do we need a change of perspective?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10430125" target="_blank" >RIV/00216208:11110/21:10430125 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/21:10430125 RIV/00216208:11130/21:10430125
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D3kx~kdHyi" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D3kx~kdHyi</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/biomedicines9080935" target="_blank" >10.3390/biomedicines9080935</a>
Alternative languages
Result language
angličtina
Original language name
Novel insights into the immunotherapy of soft tissue sarcomas: Do we need a change of perspective?
Original language description
Soft tissue sarcomas (STSs) are rare mesenchymal tumors. With more than 80 histological subtypes of STSs, data regarding novel biomarkers of strong prognostic and therapeutic value are very limited. To date, the most important prognostic factor is the tumor grade, and approximately 50% of patients that are diagnosed with high-grade STSs die of metastatic disease within five years. Systemic chemotherapy represents the mainstay of metastatic STSs treatment for decades but induces response in only 15-35% of the patients, irrespective of the histological subtype. In the era of immunotherapy, deciphering the immune cell signatures within the STSs tumors may discriminate immunotherapy responders from non-responders and different immunotherapeutic approaches could be combined based on the predominant cell subpopulations infiltrating the STS tumors. Furthermore, understanding the immune diversity of the STS tumor microenvironment (TME) in different histological subtypes may provide a rationale for stratifying patients according to the TME immune parameters. In this review, we introduce the most important immune cell types infiltrating the STSs tumors and discuss different immunotherapies, as well as promising clinical trials, that would target these immune cells to enhance the antitumor immune responses and improve the prognosis of metastatic STSs patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedicines [online]
ISSN
2227-9059
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
8
Country of publishing house
CH - SWITZERLAND
Number of pages
20
Pages from-to
935
UT code for WoS article
000688938900001
EID of the result in the Scopus database
2-s2.0-85112591649